17,261 trials
Anesthesia
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 5; 10; 9 participants
Urinary Tract Infection
Primary: Participants With Clinically-diagnosed and Treated UTI's. — 15; 30 participants
Infantile Colic
Primary: Absolute Change of the Mean Daily Crying and Fussing Time for Three Consecutive Days While on Treatment Versus Baseline. — 284.57; 273.6; 283.91; 185.8 Minutes
Aphasia
Primary: Trained Sentence Probe — 20.4; 58.8; 56.0 percentage of correct sentences
Tobacco Use Disorder
Primary: 7-day Point Prevalence Smokeless Tobacco Abstinence Biochemically Confirmed With Urine Cotinine at the End of 12 Weeks of Treatment. — 30; 23 participants
Head and Neck Cancer
Primary: Time to Progression — 44.2 Months
Monoclonal Gammopathy of Undetermined Significance · Multiple Myeloma · Smoldering Multiple Myeloma
Primary: Changes in M-protein Levels — 1.65; 2.24 g/dL — p=.23
Chronic Lymphocytic Leukemia With 17p Deletion · Small Lymphocytic Lymphoma With 17p Deletion
Primary: Overall Response Rate — 77.8 % of participants with response by PI
Relapsing-Remitting Multiple Sclerosis · Multiple Sclerosis
Primary: Summary of Treatment-emergent Adverse Events (TEAEs) Occurring Post-BG00012 Dosing (Add-on Therapy Period) — 95; 100; 72; 70 percentage of participants
Coronary Artery Disease
Primary: Platelet Reactivity by VerifyNow P2Y12 — 188; 125; 228 PRU — p=0.017
Breast Neoplasms
Primary: Percentage of Participants by Preferred Method of Drug Administration — 95.7; 87.4; 83.9; 88.5 percentage of participants
Hepatocellular Carcinoma
Primary: Subjects With Treatment Emergent Adverse Events — 23 participants
Migraine Prophylaxis
Primary: Change From Baseline in Migraine Period Frequency Per 28 Days in Treatment Phase (LOCF) — -2.94; -2.73; -3.31; -3.00 Migraine period
Diabetic Macular Edema
Primary: Percentage Change in Retinal Thickness in the Study Eye at 6 Months Compared to Baseline — -7.89 percentage change in retinal thickness
Asthma
Primary: Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) — 1.21; 1.39; 1.12; 1.33 L*hour — p=<0.0001